BACKGROUND: Although postmenopausal combined hormone replacement therapy reduces the risk of hip fracture, long-term use may be associated with an increased risk of breast cancer, and in women more than 10 years after menopause it is associated with an increased risk of cardiovascular disease. Isoflavones, because of preferential binding to estrogen receptor beta, may retain the beneficial effects on bone but lessen the adverse effects on the breast. OBJECTIVE: The objective of this study was to study the effects of an isoflavone obtained from red clover (Rimostil) on bone mineral density, and on low-density lipoprotein (LDL) cholesterol. DESIGN: In a double-blind, randomized, placebo-controlled trial, 50 mg of Rimostil was given to women who were menopausal for at least 1 year. Bone mineral density of the spine, femoral neck and forearm and serum LDL cholesterol were measured at baseline and at 6-month intervals. The duration of follow-up was 2 years. RESULTS: There was no beneficial effect of Rimostil on bone density at any site. There was a 12% fall in serum LDL cholesterol in the Rimostil-treated arm, which was significantly greater than the 2% drop seen in the control arm (P = 0.005).
INTRODUCTION
After the onset of menopause, there is a rise in the serum cholesterol and an increased risk of cardiovascular disease. 1 Menopausal women also experience frequent troublesome episodic hot flushes. The most effective therapy to diminish both the frequency and severity of hot flushes is exogenous estrogen. Estrogen therapy, when given early in menopause, is also associated with a reduction in cardiovascular events, 2, 3 but when given more than 10 years after the onset of menopause it is associated with an increased risk of cardiovascular events, including an increased risk of stroke. 4, 5 In contrast, the risk of hip fracture is reduced significantly. In addition, the use of combined estrogen and progestin for more than 5 years is associated with an increased risk of breast cancer. 4 Estradiol interacts with both the estrogen receptor α (ERα), produced in the breast and the endometrium, and the estrogen receptor β (ERβ), predominantly in trabecular bone. 6 The above considerations have led to a search for substances that interact preferentially with the estrogen receptors in bone but to a lesser extent with the estrogen receptors in the breast and endometrium. In this respect, the isoflavones produced in soy and red clover have seemed promising despite the fact that they have much less affinity for the ERβ than estradiol itself, 6 although s-equol, a metabolite of daidzein produced in the intestine, has an affinity for ERβ as high as estradiol itself but a low affinity for ERα. 7 Soy protein extracts contain mostly genistein and daidzein, whereas red clover extracts contain more biochanin A and formononetin (the precursors for genistein and daidzein, respectively).
In a previous study using red clover extract enriched with formononetin, we found that the forearm bone mineral density (BMD) increased and the serum low-density lipoprotein (LDL) cholesterol was significantly decreased in a group of postmenopausal women. 8 This study had several flaws: the absence of an appropriate placebo group, the unexpected large increases in BMD in the forearm in a 6-month period and the absence of a dose-response relationship between the fall in the serum LDL cholesterol and increasing amounts of red clover extract.
With this in mind, we have undertaken a larger double-blind, placebo-controlled study over a 2-year period, in which BMD was measured in the lumbar spine, femoral neck and forearm together with measures of serum LDL cholesterol concentrations.
Thus, the primary aim of this study was to evaluate the efficacy of Isoflavones (Formononetin enriched, P-081, Rimostil, Sydney, NSW, Australia) on vertebral body, femoral neck and forearm BMD and on serum LDL cholesterol, as measured by the within-patient changes from baseline at 24 months. Secondary end points were changes in HDL cholesterol, ApoA, ApoB, Lp(a), triglycerides, serum 25OH-vitamin D, serum calcium and urinary deoxypyridinoline (DPYR). The hemoglobin and serum alanine aminotransferase (ALT) were measured to assess potential adverse effects of the active treatment.
25OH-vitamin D level440 nmol/l and a BMD T-score 4 − 2.0 in the spine and hip. Nine participants whose serum 25OH-vitamin D levels were subsequently found to be less than 40 nmol/l were inadvertently randomized and continued in the trial. The mean 25OH-vitamin D levels at baseline and at 6, 12, 18 and 24 months were not significantly different between active treatment and placebo groups. The mean age of participants was 54 ± 4 (s.d.) years.
Participants were excluded if hormone replacement therapy had been taken within 2 months of screening into the study, if there was a history of clinical vertebral fracture or other minimal trauma fracture or if they had any intercurrent medical condition, such as celiac disease, primary hyperparathyroidism, renal impairment or thyroid overactivity, that would be likely to confound the study outcome. Participants were also excluded if they had previously taken bisphosphonates, strontium, fluoride or raloxifene or if they were a vegetarian consuming more than 10 gm of legume daily. None of the participants took any of these bone-preserving medications during the study, and participants were instructed not to take soy or red clover products during the 2-year study period and to keep a food diary so that food intake could be assessed.
A total of 183 participants were initially screened for the study; 30 participants were excluded because of failure to meet the study's inclusion/exclusion criteria and 6 participants withdrew consent before randomization. In all, 147 participants entered into the study and were randomized: 75 participants in the active treatment group and 72 participants in the control group.
A full medical examination was performed on each participant at entry into the study and annually throughout the 2-year period. BMD measurements were performed every 6 months on the AP spine (L2-L4) and femoral neck using the Norland XR36 densitometer (Fort Atkinson, WI, USA), and the proximal and distal radius using the Norland pDEXA scanner (Fort Atkinson, WI, USA). Both scanners were calibrated and an external phantom was used to monitor quality control on a daily basis. From 2002, because of the involvement of the site in an international clinical trial, an additional external Hologic phantom (Bedford, MA, USA) was also incorporated into the Norland XR36 daily quality control regimen and monitored by Synarc (Portland, OR, USA) (coefficient of variation 0.26-0.55%). The monthly average measurements of the Hologic phantom between 2002 and 2007 varied between 99.6 and 100.4% of the designated value. A thoracolumbar spine X-ray was performed at entry into, and at the conclusion of, the study.
Fasting blood samples were collected every 6 months for the measurement of serum total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, ApoA, ApoB, triglycerides, Lp(a), serum calcium and serum 25OH-vitamin D. Biochemical safety measures to assess the safety of the active medication included serum ALT and hemoglobin. A fasting 2-hour second void morning urine sample was also collected every 6 months for the measurement of urine DPYR.
A trans-vaginal ultrasound to measure endometrial thickness was performed at entry into, and at the conclusion of, the study.
Study participants were also asked to monitor their menopausal symptoms throughout the study using a Greene Climacteric Scale 9 diary; each of the 21 items in the Greene Climacteric Scale were graded 0-3 in severity so that the maximum score possible was 63; and they were also encouraged to write down any adverse events or the use of concomitant medications in the diary.
Laboratory Assays: The serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, ApoA and ApoB were measured using the Roche modular assay system (Roche Diagnostics, Basel, Switzerland). The Lp(a) was measured initially with a Biopool ELISA assay (Umea, Sweden) and subsequently with a Mercodia (Upsala, Sweden) ELISA assay (CSLS). Serum 250H-vitamin D was measured between 2000 and 2005 using the Nichols Advantage (San Clemente, CA, USA) assay (inter-assay variation 10-14%) and from the 22 July 2005 using the Diasorin Liaison (Saluggia, Italy) assay. The assays were cross-correlated (Diasorin Liaison = 1.07 Nichols+18, r = 0.794). The Nichols serum 25OD-vitamin D values were transformed into Diasorin Liaison equivalents using this equation. Urinary DPYR was measured using the Siemens (Erlangen, Germany) Immulite assay with an inter-assay variation of 9-15%.
Each study participant was asked to take two tablets of the study drug daily: this was either P-081 (marketed since as Rimostil), with each tablet containing 25 mg of isoflavone predominantly formononetin and biochanin, or placebo, which was identical in shape, size and color. Both groups of women were given supplemental calcium (CalSup) at a dose of 1000 mg per day. Compliance with the study medication was assessed by pill counts at each study visit.
Randomization was performed in blocks of 6 in a 1:1 design. The study participants and all of the study staff members were blinded to the treatment.
The study was approved by the Royal North Shore Hospital Human Research Ethics Committee and conducted according to ICH-GCP guidelines. Each study participant provided written informed consent.
Sample size calculation
The five primary outcome variables were the within-patient change from baseline at 24 months for BMD of the spine, femoral neck, proximal and distal radius and for serum LDL cholesterol. Differences between the active and control arms were tested at the 1.0% significance level for each of these outcomes in order to maintain an overall 5% significance level for the primary outcomes. Previous experience in our department suggested that the standard deviation of the within-patient percentage change from baseline BMD at any of the four sites would not exceed 3.4%. 10 A sample size of 65 per arm ensures 80% power to detect a difference of at least 2% between the mean within-patient percentage change from baseline observed in the active and control arms at 24 months. A sample size of 71 per arm was recommended to allow for up to 10% discontinuation.
Statistical analyses
Throughout the trial, the data were collected and collated by an independent manager. Novogen (Sydney, NSW, Australia), who supplied the study medication, had no role in the collection or analysis of the study data or in the submission of the manuscript for publication. The analysis was carried out by an independent professional statistician, and all authors vouch for the integrity of the data.
The statistical software packages S-PLUS Version 8 (TIBCO Software Inc., Palo Alto, CA, USA) and SPSS version 21 (IBM Corporation, Armonk, NY, USA) were used to analyze the data by the intention-to-treat principle. Two-tailed tests were used throughout. Each of the five primary outcome variables was tested at a significance level of 1% in order to maintain an overall 5% level. Exploratory analyses were used to test each of the secondary outcomes at the 5% significance level. Two-sample t tests (or Mann-Whitney tests for the highly skewed Lp(a) and ALT variables) were used to test for imbalances between the treatment arms at baseline (see Table 1 ).
Linear mixed-effects (LME) models 11 were fitted to the spine, femoral neck, proximal radius and distal radius BMD measurements, to the serum LDL, HDL and total cholesterol, to the triglycerides, ApoA, ApoB, serum calcium, serum 25OH-vitamin D, urine DPYR, hemoglobin and logtransformed Lp(a) and ALT measurements and to the Greene score, systolic and diastolic blood pressure measurements. Treatment (active or placebo), time and their two-way interaction were considered as fixed effects. The patient identifier and time were considered as random effects. Time was considered as a factor with five levels (baseline 0, 6, 12, 18 and 24 months). In the LME models used to assess linear trends within the patient over time, time was considered as a continuous covariate. Normal Q-Q plots were used to assess whether the residuals from the fitted models showed any obvious departure from the underlying assumption of normality.
The LME models included treatment and time as a five-level factor. The two-way interaction between these terms provided effect estimates which are summarized in Table 2 . For all outcome measures, a significant interaction between the effects of treatment and time was interpreted as evidence of a difference between the within patient changes observed over time in both the control and active arms of the study.
Many exploratory analyses of secondary outcome measures were performed and false positive results may have occurred. Any such findings should be treated with caution and confirmed in further independent studies.
RESULTS
The patient characteristics at baseline by treatment arm are listed in Table 1 . With the exception of triglycerides (control group lower than active), there were no significant differences between treatment arms at baseline.
A total of 20 participants in the active arm withdrew from the study before study completion. Of these, 15 dropped out in the first 6 months. In all, 30 participants in the control arm withdrew from the study, and of these 19 dropped out in the first 6 months. The most common reason for withdrawal from the study was worsening of menopausal symptoms. Study participants were not told to expect any change in the frequency of hot flushes during the study period. A total of 55 participants in the active arm and 42 in the control arm completed the 2-year study as per protocol. Figure 1 .
If patients dropped out of the study in the first few weeks, they were excluded from the pill count analysis. Not all the patients were diligent in returning their study medications at the end of each 6-month period. Where data were available, compliance was almost identical in the active arm (88% ± 15%) and in the control arm (89 ± 13%). In all, 21 of those receiving active treatment and 29 of those receiving placebo did not record any pill count. Urinary isoflavones were not measured in this study.
In all, 110 participants had a pelvic ultrasound at the time of entry into the study. Endometrial thickness was normal ( o6 mm) in all except one participant, where it was noted to be 9 mm. A curette was performed by the participant's gynecologist; endometrial histology was found to be normal and the participant continued in the study. Fifty-eight participants had a further pelvic ultrasound at Month 24. One patient in the placebo arm had an endometrial thickness of 11 mm; a repeat ultrasound was performed a few months later and was normal.
A total of 142 participants had an X-ray of their thoracolumbar spine at the baseline visit. Vertebral wedging was reported in 14 participants: minor wedging in the thoracic spine was reported in 10 participants, significant wedging in the thoracic spine in 3 participants and significant wedging in the third lumbar vertebra in 1 participant. Ninety participants had further X-rays at Month 24. Thoracic vertebral compression not previously present at the baseline X-ray was reported in five participants: two in the active arm and three in the control arm. No incidence of a clinical vertebral fracture was reported in either arm.
There was no significant evidence of any difference between treatments in the within-patient changes observed over time for the primary outcomes of BMD of the spine, femoral neck, distal radius or proximal radius (all P-values for the time by treatment interactions 40.25) ( Table 2 ). Across both the active and control arms, there was a statistically significant decrease over time in the BMD of the spine, femoral neck, distal radius and proximal radius (test for linear within patient trend P = 0.008, Po 0.001, Po 0.001 and P o 0.001, respectively).
Five participants, four in the active arm and one in the control arm, commenced statin therapy during the study. The lipid parameters of these participants were excluded from all lipid analyses presented in Table 2 (the lipid results were virtually identical when the five participants were included). There was significant evidence of a difference between treatments in the within-patient changes observed over time for the primary outcome of serum LDL cholesterol (P = 0.005 for time by treatment interaction) and for serum total cholesterol (P = 0.015). In particular, a significant reduction was seen at each time point for the active arm, and this reduction was significantly greater than any change observed in the control arm at all time points except 12 months for both serum LDL cholesterol and for serum total cholesterol (Figure 2 ).
There was no significant evidence of any difference between treatments in the within-patient changes observed over time for urinary DPYR or serum 25OH-vitamin D (Table 2) . Across both the active and control arms, there was a statistically significant reduction in serum 25OH-vitamin D over time (test for linear within-patient trend Po 0.001). There was no significant evidence of any difference between treatments in the within-patient changes observed over time for serum calcium, serum ALT (as a marker of liver function) and hemoglobin, nor was there any significant overall linear within-patient trend with time in any of these variables (data not shown).
There was no significant evidence of any difference between treatments in the within-patient changes observed over time for serum HDL cholesterol or for serum triglycerides (Table 2) . Linear trend analyses showed a significant overall within-patient increase in HDL cholesterol and a significant overall within-patient decrease in serum triglycerides with time, neither of which differed significantly by treatment (P o0.001 and P = 0.012, respectively, for linear within-patient trend with time across active and control arms). There was no significant evidence of any difference between treatments in the within-patient changes observed over time for serum ApoA, ApoB or serum Lp(a) (time by treatment interaction P = 0.744, 0.056 and 0.089, respectively).
Coagulation factors were measured in 15 participants in the active arm and 11 in the placebo arm. There was no significant difference between the two groups for the prothrombin time, APTT, serum fibrinogen and factor VIII (data not shown).
There was no significant evidence of a difference between treatments in the within-patient changes observed over time for the Greene climacteric scores (time by treatment interaction P = 0.855). The average body mass index of the control group at the completion of the study was 25.3 ± 4.1 (s.d.) compared with 26.3 ± 4.2 (s.d.) in the active group. (P = 0.150). Significant withinpatient decreases from baseline to month 24 were observed for systolic and diastolic BP in both the active and control arms (P o 0.05 in all instances). However, the decreases were comparable in both arms (P = 0.703 for systolic and P = 0.540 for diastolic BP) ( Table 2) . ; total cholesterol, triglycerides, HDL and LDL, mmol/l; ApoA and ApoB, g/l; Lp (a), mg/l; serum calcium, mmol/l; serum ALP, U/l; serum 25OH-vitamin D, nmol/l; DPYR (urine deoxypyridinoline), nmol/mmol creatinine; Hemoglobin, g/l. a two-sample t test (or Mann-Whitney test for the skewed lipoprotein (a) and ALT).
Red clover isoflavones, LDL cholesterol, Bone mineral density PB Clifton-Bligh et al Table 2 . Estimated mean within-patient change from baseline and associated 95% CI from the linear mixed-effects model involving time, treatment and their interaction
Variable Treatment
Change from baseline at 6mths
Change from baseline at 12mths
Change from baseline at 18mths
Change from baseline at 24mths
Time test of difference between active and placebo within-patient change from baseline at specified time.
Adverse events Several serious adverse events occurred during the study: in the active arm, one participant withdrew 3 weeks after randomization with a diagnosis of colon carcinoma, and another participant in this arm lost 22 kg in weight, and despite full investigation as to other probable causes, may have been due to voluntary excessive caloric restriction. Other reported adverse events in the active arm include biopsy-confirmed benign thyroid nodules (n = 2), bowel obstruction (n = 2, one small bowel and one large bowel) and type 2 diabetes, duodenal ulcer, gastric ulcer and celiac disease (all n = 1). In the control arm, one participant suffered a subarachnoid hemorrhage after a fall from which she recovered. Another patient died of a ruptured berry aneurysm. Other reported adverse events in the placebo arm include superficial thrombophlebitis (n = 2), biopsy-confirmed benign thyroid nodules (n = 2), deep-vein thrombosis, diverticulitis, gastric ulcer, biliary colic, cholecystitis, abnormal LFTs of unknown cause, which recovered spontaneously, fractured L4 and fractured ribs (all n = 1). Sinusitis, upper respiratory tract infection, urine tract infection, muscle and joint pain were common in both treatment arms. Several participants were troubled by constipation.
There was no instance of breast cancer in either treatment arm, and although participants were encouraged to maintain regular government-funded 2-yearly mammograms, systematic mammograms were not carried out during the study.
DISCUSSION
The findings of the studies showing an increased risk of breast cancer and cardiovascular disease in postmenopausal women receiving estrogen and progesterone therapy have led to the search for alternative agents, which might retain the benefits of estrogen therapy, with a concomitant reduction in the risk of adverse effects. Estrogen exerts its effects by binding to ERα and ERβ 6, 12 and also by influencing the function of cell kinases through interaction with the estrogen receptor. 13 ERβ is found predominantly in bone, whereas ERα is significantly expressed in the breast and endometrium but also significantly in bone. It is ERβ and not ERα that mediates the reduction in sclerostin with changes in estradiol and mechanical loading. 14 Isoflavones have estrogen-like activity and bind preferentially to ERβ but with a much lower affinity than estradiol. 6 Soy and red clover extracts contain isoflavones; soy isoflavones consist predominantly of genistein and daidzein, whereas red clover isoflavones consist predominantly of formononetin and biochanin. Biochanin is converted into genistein and formononetin into daidzein, and it is not certain whether formononetin and biochanin have any intrinsic biologic activity before conversion. Genistein has 20-30 times the binding affinity for ERβ compared with ERα. The binding affinity of biochanin to estrogen receptors is 10 000 times less than estradiol. 6 Formononetin stimulated ERβ-dependent beta galactosidase production to a greater extent than via ERα. 15 However, formononetin stimulated osteoblast differentiation via the MAP kinase pathway and did not activate the osteoblast ER. 16 Genistein also enhanced osteoblast differentiation by the p38 MAP kinase pathway 17 and reduced the RANKL/OPG mRNA expression ratio in human osteoblasts. 18 Early studies with soy isoflavones in ovariectomized rats showed the prevention of trabecular and cortical bone loss. 19, 20 Biochanin maintained femoral BMD and formononetin restored femoral and tibial trabecular architecture 21, 22 in ovariectomized rats. Red clover isoflavones, however, did not reduce bone resorption from bone prelabeled with 41 Ca. 23 Treatment of postmenopausal women with soy isoflavones and red clover isoflavones have produced variable results. A summary of the effect of isoflavones on BMD is shown in Table 3 . [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Some studies showed a preservation of particularly hip BMD, [29] [30] [31] [32] [33] especially with genistein. [29] [30] [31] Red clover isoflavones enriched with biochanin were associated with preservation of spinal BMD. 35 In our present study using red clover isoflavones enriched with formononetin, there was no impact on the rate of loss of BMD over a 24-month period at the spine, hip and forearm, which proceeded at a rate expected in the postmenopausal state. Zhang et al. 36 showed in a large Shanghai population study that high dietary soy protein intake was associated with a significant reduction in fracture rate. A typical soy diet consists of 15-50 mg/ day of isoflavones. 37 Many of the studies using soy isoflavones involved much higher doses of isoflavones rich in genistein and daidzein. It is possible that other factors in soy extract apart from isoflavones may have a role in reducing incident fractures.
Another potential benefit of isoflavones might be to lower serum LDL cholesterol. The lipid-lowering effects of isoflavones have been variable in postmenopausal women, summarized in Table 4 . In most studies using soy isoflavones, there was no change in serum LDL cholesterol, 25, 31, [38] [39] [40] [41] whereas a significant fall occurred in two studies. 33, 42 A meta-analysis of studies using soy isoflavones 43 showed a significant, albeit small, reduction in serum LDL of 0.13 mmol/l (P o 0.0001). With red clover isoflavones, there was no change in serum LDL cholesterol in five studies [44] [45] [46] [47] [48] and a significant fall of 11.6% in one study. 49 In our study using red clover isoflavones enriched with formononetin at 50 mg/day and conducted over a 24-month period, there was a significant fall in the serum LDL cholesterol, which was first observed at 6 months and maintained at 24 months. The serum LDL cholesterol in the treated arm fell by 12% from 3.68 mmol/l to 3.25 mmol/l, a drop of 0.43 (95% CI -0.26-0.60) versus a nonsignificant decline in the control arm of 0.07 ((95% CI -0.11-0.24).
Gould, 50 in a large population study, showed that for every 1 mmol/l reduction in serum LDL cholesterol there was a 15.6% reduction in all-cause mortality and a 28% reduction in coronary heart disease mortality. Bush et al. 51 followed up women aged 40-49 years for 8.5 years and there was a significant reduction in death from cardiovascular disease in estrogen users (RR = 0.34), and the reduction in mortality was related to a rise in the HDL cholesterol. When statins were used to reduce serum LDL cholesterol, for a 1 mmol/l reduction in serum LDL cholesterol, the risk ratio for mortality was 0.79 irrespective of the baseline serum cholesterol and the presence or absence of previous vascular disease. 52 In a Lipid Research Clinics' coronary primary prevention trial in men, a 12.6% reduction in serum LDL cholesterol was associated with a 19% reduction in myocardial infarction. 53 In a Shanghai cohort of middle-and older-aged women, the risk of coronary heart disease fell by 75% in those consuming a high-soy protein diet, 54 although this benefit cannot be attributed to the impact of isoflavones specifically. Isoflavones fed to cynomolgus monkeys was associated with a significant reduction in the extent of atherosclerosis. 55 The exact mechanism whereby isoflavones may lower serum LDL cholesterol is unclear. In ovariectomized rats deprived of estradiol, hepatic expression of LDL receptor and PcsK9 is reduced and restored by estradiol supplementation. 56 Soy isoflavones at 91 mg/day for 2.7 years reduced the rate of progression of atherosclerosis, as measured by a change in carotid artery intima-media thickness in postmenopausal women within 5 years of the onset of menopause. 57 Promensil and formononetin improved systemic arterial compliance. 45, 58 Aortic stiffness measured as pulse-wave velocity is strongly associated with atheroclerosis 59 and with cardiovascular mortality, 59, 60 and thus cardiovascular benefits of isoflavone therapy may occur independently of any change in serum LDL cholesterol.
We did find a significant lowering of blood pressure over the 24-month period of our study, but there was no significant difference between the active treatment and control groups. Red clover isoflavones enriched with formononetin 61 and a metabolite of formononetin 62 reduced systolic and diastolic blood pressure in postmenopausal women and formononetin had an antihypertensive effect in spontaneously hypertensive male rats. 63 The isoflavone genistein, 54 mg/day, significantly reduced the frequency of hot flushes in postmenopausal women. 30, 31 The red clover extract, Promensil, reduced the frequency of hot flushes. 64 Rimostil, 82 mg/day, given over a 12-week period had no impact on the frequency of hot flushes, 65 and in our study, Rimostil, 50 mg/day, also had no significant effect on menopausal symptoms evaluated by the Green Climacteric Scale.
There are several possible limitations to the interpretation of the results. The number of participants recruited may not have been large enough to allow the ascertainment of significant differences in BMD between the two treatment groups. However, the effect sizes measured for within-person changes would suggest that even if much larger numbers were studied a significant benefit of Rimostil on BMD would not have been seen. The larger number of dropouts from the inactive treatment group versus the active treatment group may have skewed results in an unpredictable way.
In summary, the present study has shown that, compared with placebo, 50 mg/day Rimostil significantly lowers the primary outcome variable of serum LDL cholesterol over 24 months. The improvement is evident by 6 months. Our previous study 8 also showed a significant reduction in serum LDL cholesterol with Rimostil. In contrast to our previous study, the use of Rimostil compared with placebo did not significantly alter the loss of BMD in the forearm, or in the lumbar spine and femoral neck. It is possible that the binding of the isoflavones in Rimostil to the ERβ was too weak to prevent loss of BMD. There was no adverse effect on endometrial thickness. The constellation of adverse effects in patients taking Rimostil was no different from those seen in the control group. It is uncertain whether the fall in the serum LDL cholesterol might lead to a change in the risk of cardiovascular disease, or whether the observed fall in the serum LDL cholesterol with Rimostil would augment any fall in the serum LDL cholesterol brought about by other agents such as statins. assessment of each participant throughout the trial. PBC-B and KB made major contributions to the writing of the manuscript and take responsibility for the validity of the data. KB performed statistical analyses of the data. SV died during the course of the study. All other authors have read and approved the final manuscript.
